Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 3.87 is 12% below its 5-year average of 4.42, around the middle of its 5-year range (2.15–7.10).
As of the fiscal period ended Tuesday, June 30, 2026. 17.08% below its 12-month average of 4.66.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.87.
CURRENT RATIO
3.87
CURRENT RATIO AVG TTM
4.66
CURRENT RATIO AVG 3Y
4.79
CURRENT RATIO AVG 5Y
4.42
CURRENT RATIO AVG 10Y
4.66
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-17.08%
CURRENT VS 3Y AVG
-19.32%
CURRENT VS 5Y AVG
-12.46%
CURRENT VS 10Y AVG
-16.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+3.07%
vs the sector median at left
iRhythm Technologies, Inc.
Market Cap
$3.52B
Current Ratio
3.87
TTM Avg
4.66
3Y Avg
4.79
5Y Avg
4.42
Market Cap
$3.54B
Current Ratio
21.02
TTM Avg
15.64
3Y Avg
20.34
5Y Avg
22.11
Market Cap
$3.48B
Current Ratio
10.45
TTM Avg
13.16
3Y Avg
14.41
5Y Avg
11.78
Market Cap
$3.57B
Current Ratio
50.82
TTM Avg
11.65
3Y Avg
9.40
5Y Avg
9.07
Market Cap
$3.64B
Current Ratio
1.42
TTM Avg
24.66
3Y Avg
24.23
5Y Avg
16.18
Market Cap
$3.38B
Current Ratio
3.39
TTM Avg
3.10
3Y Avg
3.17
5Y Avg
4.31
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iRhythm Technologies, Inc. (IRTC) | $3.52B | 3.87 | 4.66 | 4.79 | 4.42 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | 21.02 | 15.64 | 20.34 | 22.11 |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 9.16 | 6.44 | 5.38 | 7.95 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | 10.45 | 13.16 | 14.41 | 11.78 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | 50.82 | 11.65 | 9.40 | 9.07 |
| Celcuity Inc. (CELC)vs › | $3.47B | 8.93 | 9.13 | 14.29 | 16.91 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 9.63 | 11.21 | 9.89 | 7.80 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | 1.42 | 24.66 | 24.23 | 16.18 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 3.39 | 3.10 | 3.17 | 4.31 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 17.91 | 1.68 | 1.68 | 1.68 |
Current Ratio
3.87
Quick Ratio
3.75
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 3.87 |
| 2026-03-31 | 5.17 |
| 2025-12-31 | 4.63 |
| 2025-09-30 | 4.63 |
| 2025-06-30 | 5.02 |
| 2025-03-31 | 5.71 |
| 2024-12-31 | 5.82 |
| 2024-09-30 | 6.27 |
| 2024-06-30 | 6.92 |
| 2024-03-31 | 7.10 |
| 2023-12-31 | 2.15 |
| 2023-09-30 | 2.29 |
| 2023-06-30 | 2.71 |
| 2023-03-31 | 3.10 |
| 2022-12-31 | 3.24 |
| 2022-09-30 | 3.42 |
| 2022-06-30 | 4.04 |
| 2022-03-31 | 4.63 |
| 2021-12-31 | 3.48 |
| 2021-09-30 | 3.93 |
| 2021-06-30 | 4.60 |
| 2021-03-31 | 5.66 |
| 2020-12-31 | 5.75 |
| 2020-09-30 | 6.55 |
| 2020-06-30 | 3.10 |
| 2020-03-31 | 3.60 |
| 2019-12-31 | 3.32 |
| 2019-09-30 | 4.15 |
| 2019-06-30 | 2.66 |
| 2019-03-31 | 3.27 |
| 2018-12-31 | 3.52 |
| 2018-09-30 | 4.79 |
| 2018-06-30 | 5.58 |
| 2018-03-31 | 6.59 |
| 2017-12-31 | 5.72 |
| 2017-09-30 | 7.65 |
| 2017-06-30 | 8.15 |
| 2017-03-31 | 9.98 |
| 2016-12-31 | 8.98 |
| 2016-09-30 | 1.91 |
| 2016-06-30 | 2.56 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 3.74 |
| 2015-09-30 | 2.20 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 3.20 |
